CHM SURVEY TRIAL

Actively Recruiting // Choroideremia // Clinical Trials // Inherited Retinal Degeneration // Kimberly Stepien // Dec 01 2020

Choroideremia (CHM) Health Outcomes

  • Sponsor: Biogen MA, Inc.
  • Principal Investigator: Kimberly Stepien, MD
  • Study Coordinator: Nickie Stangel

Study objective:

To assess health-related quality of life, health utility, work productivity, and impact on daily activities in patients/caregivers with CHM at different stages of disease progression.

Study design:

Patients will complete a one-time study questionnaire in the office or online. As available, patient caregivers will also be asked to complete a one-time study questionnaire.

Inclusion criteria:

  • Male patients ≥ 5 years of age
  • CHM diagnosis confirmed via genetic testing
  • At least one record of visual acuity and visual field measurement in the past 12 months

Exclusion criteria:

  • Patients who have received gene therapy or any other investigational treatment

Contact Nickie Stangel with questions, 608-263-8783